RxDoctor Payments Data

Sakib Khalid, MD

Gastroenterology · Indianapolis, INNPI 1760582365

Payments from drug & device makers

$1,756in general payments, 2019–2025

Across 109 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$320
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$291
  • Takeda Pharmaceuticals U.S.A., Inc.$231
  • Johnson & Johnson$194
  • Gilead$124
  • Phathom Pharmaceuticals, Inc.$121
  • plus $475 from 12 others

What the payments were for

  • Food & beverage$1,68396%
  • Gifts$734%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,756 in reported general payments places this provider in the 40th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$52,241
Medicare patients
251
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab38$258,155
LinzessLinaclotide154$101,163
XifaxanRifaximin16$41,508
Mesalamine38$17,593
Dexlansoprazole DrDexlansoprazole45$9,350
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates73$4,410
Esomeprazole Magnesium85$3,596
Lubiprostone26$3,430
Colestipol Hcl27$3,106
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl209$3,032
Dicyclomine Hcl94$2,217
Ondansetron OdtOndansetron70$1,940
Pantoprazole Sodium180$1,824
Ursodiol12$1,085
Omeprazole82$1,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$320$101,163154 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$291$41,50816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →